switching therapy in polycythemia vera
Published 6 years ago • 132 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
4:26
polycythemia vera: switching therapy
-
2:12
initiating cytoreductive therapy in polycythemia vera
-
3:45
ruxolitinib as second-line therapy in polycythemia vera
-
3:32
rationale for switching polycythemia therapy
-
6:15
initial treatment for polycythemia vera
-
4:52
treating pv with jak inhibition now and in the future
-
4:26
controlling hematocrit in polycythemia vera
-
5:10
monitoring pv: when to initiate a change in therapy?
-
2:16
the future of polycythemia vera treatment
-
4:43
the role of ruxolitinib in treating polycythemia vera
-
6:39
ruxolitinib patient selection in polycythemia vera
-
2:59
using hydroxyurea in a patient with polycythemia vera
-
6:07
available treatment options for patients with pv
-
4:41
polycythemia vera disease burden
-
3:01
improved understanding of jak2 inhibition in polycythemia vera
-
0:57
moving beyond hydroxyurea in polycythemia vera
-
3:30
polycythemia vera: treatment goals & risk stratification
-
7:17
role of phlebotomy in polycythemia vera
-
2:39
considerations when assessing patients suspicious of pv